Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.
UK surgeons remotely removed a man’s prostate cancer from 1,500 miles away in the country’s first successful robot-assisted telesurgery.
Thirty-eight years ago, I was initiated into the oldest and one of the largest Black fraternities in the world: Alpha Phi Alpha Fraternity, Inc. It was one of the happiest days of my life. In ...
The European Society for Medical Oncology has updated its clinical practice guidelines for the management of localised prostate cancer and biochemical recurrence, refining diagnostic pathways and ...
Cancer charity highlights apparent ‘postcode lottery’ of testing and diagnoses across different regions seen in study Prostate cancer is now the most commonly diagnosed form of cancer across the UK, ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...
A newly uncovered mechanism thought to be a weakness of prostate cancer cells could inspire a new and improved targeted treatment for the disease. International research led by Flinders University in ...
California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results